Loading...
•
Jun 30, 2022
ANI Pharmaceuticals Q2 2022 Earnings Report
ANI Pharmaceuticals reported record net revenues and raised full-year 2022 net revenue guidance for Purified Cortrophin® Gel.
Key Takeaways
ANI Pharmaceuticals reported a record-breaking second quarter with net revenues of $73.9 million, driven by Purified Cortrophin® Gel sales and growth in generic pharmaceuticals. The company raised its full-year 2022 net revenue guidance for Purified Cortrophin® Gel.
Net revenues reached $73.9 million, marking a new quarterly record.
Purified Cortrophin® Gel achieved net sales of $10.2 million.
Adjusted non-GAAP diluted earnings per share was $0.13.
Generics business ranked sixth in number of ANDAs approved in last 12 months.
Forward Guidance
ANI Pharmaceuticals provided full-year 2022 guidance, reiterating total Company net revenue guidance of $295 to $315 million, adjusted non-GAAP EBITDA guidance of $54 million to $60 million, adjusted non-GAAP Earnings Per Share between $1.34 and $1.62, and raising Cortrophin 2022 net revenue guidance to $40 million to $45 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...